Epigenic Therapeutics Raises $20 Million In Series Angel And Pre-A Funding To Advance Next Generation Gene Editing Therapy

Aug 06, 2022•about 3 years ago

Amount Raised

$20 Million

Round Type

series a

ShanghaiBiotechnologyHealth CareGeneticsTherapeutics

Description

Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured $20 million in Series Angel and Pre-A funding. Series Pre-A funding is jointly invested by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating.

Company Information

Company

Epigenic Therapeutics

Location

Shanghai, Shanghai, China

About

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases. For more information, visit www.epigenictx.com

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech